Zhu, Jun
Peking University Cancer Hospital
3 papers on CoChatORCID 0000-0003-3479-2547
Most cited papers
- Verified
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
van Rhee, F., Wong, R. S., Munshi, N., Rossi, J.-F., Ke, X.-Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R. K., et al. (2014) · The Lancet Oncology
Viral-associated cancers and disordersLymphadenopathy Diagnosis and Analysis
Cited by 454
- Verified
AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma
Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 434
- Verified
Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
Sun, Y., Ding, N., Song, Y., Yang, Z., Liu, W., Zhu, J., & Rao, Y. (2019) · Leukemia
Protein Degradation and InhibitorsChronic Lymphocytic Leukemia Research
Cited by 148
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free